Unknown

Dataset Information

0

Amygdala electrical-finger-print (AmygEFP) NeuroFeedback guided by individually-tailored Trauma script for post-traumatic stress disorder: Proof-of-concept


ABSTRACT: Highlights • Randomized clinical trial with a novel self-neuromodulation training in PTSD.• Demonstration of feasibility of an fMRI-informed EEG model of Amygdala modulation (AmygEFP).• Individually-tailored trauma-related content as the training feedback interface.• Results showed reduction of PTSD symptoms following AmygEFP trauma-related feedback training.

Background

Amygdala activity dysregulation plays a central role in post-traumatic stress disorder (PTSD). Hence learning to self-regulate one's amygdala activity may facilitate recovery. PTSD is further characterized by abnormal contextual processing related to the traumatic memory. Therefore, provoking the personal traumatic narrative while training amygdala down-regulation could enhance clinical efficacy. We report the results of a randomized controlled trial (NCT02544971) of a novel self-neuromodulation procedure (i.e. NeuroFeedback) for PTSD, aimed at down-regulating limbic activity while receiving feedback from an auditory script of a personal traumatic narrative. To scale-up applicability, neural activity was probed by an fMRI-informed EEG model of amygdala activity, termed Amygdala Electrical Finger-Print (AmygEFP).

Methods

Fifty-nine adults meeting DSM-5 criteria for PTSD were randomized between three groups: Trauma-script feedback interface (Trauma-NF) or Neutral feedback interface (Neutral-NF), and a control group of No-NF (to control for spontaneous recovery). Before and immediately after 15 NF training sessions patients were blindly assessed for PTSD symptoms and underwent one session of amygdala fMRI-NF for transferability testing. Follow-up clinical assessment was performed at 3- and 6-months following NF treatment.

Results

Patients in both NF groups learned to volitionally down-regulate AmygEFP signal and demonstrated a greater reduction in PTSD symptoms and improved down-regulation of the amygdala during fMRI-NF, compared to the No-NF group. The Trauma-NF group presented the largest immediate clinical improvement.

Conclusions

This proof-of-concept study indicates the feasibility of the AmygEFP-NF process-driven as a scalable intervention for PTSD and illustrates its clinical potential. Further investigation is warranted to elucidate the contribution of AmygEFP-NF beyond exposure and placebo effects.

SUBMITTER: Fruchtman-Steinbok T 

PROVIDER: S-EPMC8551212 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8258802 | biostudies-literature
| S-EPMC4072124 | biostudies-literature
| S-EPMC6737344 | biostudies-literature
| S-EPMC10035884 | biostudies-literature
| S-EPMC9033548 | biostudies-literature
| S-EPMC5838530 | biostudies-literature
| S-EPMC9204632 | biostudies-literature
| S-EPMC4857073 | biostudies-literature
| S-EPMC6602157 | biostudies-literature
| S-EPMC10785722 | biostudies-literature